Compass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at Guggenheim

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating restated by analysts at Guggenheim in a report released on Tuesday,Benzinga reports.

Other analysts have also recently issued research reports about the stock. Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. D. Boral Capital restated a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday. HC Wainwright restated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research note on Monday. Finally, Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Compass Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $1.87 on Tuesday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The firm has a market capitalization of $257.90 million, a price-to-earnings ratio of -5.03 and a beta of 1.40. The business has a fifty day moving average of $2.33 and a 200 day moving average of $2.09.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insider Buying and Selling

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new position in Compass Therapeutics in the 4th quarter valued at approximately $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $27,000. Mariner LLC bought a new stake in Compass Therapeutics in the fourth quarter valued at about $30,000. Finally, Squarepoint Ops LLC bought a new position in shares of Compass Therapeutics during the 4th quarter worth approximately $35,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.